PGD Recombinant Monoclonal Antibody

6-phosphogluconate dehydrogenase (PGD) serves as a critical enzyme in the pentose phosphate pathway, catalyzing the oxidative decarboxylation of 6-phosphogluconate to ribulose-5-phosphate while generating NADPH. This metabolic role positions PGD at the intersection of cellular biosynthesis and redox homeostasis, making it increasingly relevant to researchers investigating cancer metabolism, oxidative stress responses, and metabolic reprogramming in disease states.

This recombinant rabbit monoclonal antibody, clone 9G9, offers the reproducibility and consistency that demanding experimental workflows require. Generated against a synthetic peptide derived from human PGD protein, the recombinant format ensures sequence-defined specificity and eliminates the lot-to-lot variability that can complicate longitudinal studies or multi-site collaborations. Affinity chromatography purification further enhances signal clarity by removing non-specific immunoglobulins.

Validation studies demonstrate reliable performance across multiple detection platforms. Immunohistochemistry on paraffin-embedded human breast cancer tissue reveals clear cytoplasmic staining when used at dilutions between 1:50 and 1:200, with optimal results observed at 1:100 using citrate buffer antigen retrieval. Flow cytometry analysis in HepG2 hepatocellular carcinoma cells confirms intracellular detection capability, showing distinct positive population shifts compared to isotype controls when cells are fixed and permeabilized. This dual-platform validation provides researchers flexibility in experimental design, whether examining PGD expression in archival tissue specimens or quantifying protein levels in cultured cell populations.

For investigators exploring signal transduction pathways, metabolic enzyme regulation, or the emerging connections between pentose phosphate pathway activity and cellular proliferation, this antibody delivers the technical reliability needed to generate meaningful, reproducible data.